GC Biopharma registers Phase 2/3 trial of GC3114B in adults 65 years or older
The study plans to enroll 1806 participants and is expected to begin in October 2026. It is a multicenter, randomized, double-blind, active-controlled trial that will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.
Primary source
ClinicalTrials.gov registry record, October 20, 2026
Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
Read the source: Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation